Clinical Experience with Visken, (Prindolol) in Essential Hypertension: Its Special Comparative Action to Aldomet (Methyldopa)
- 1 September 1973
- journal article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 1 (6) , 561-566
- https://doi.org/10.1177/030006057300100609
Abstract
There is sound statistical evidence that Visken in thirty randomly selected cases was on the average more effective than Aldomet. The results also show that Visken is an excellent drug to lower both systolic and diastolic pressures without a marked effect on posture. Higher systolic and diastolic pressures are lowered more effectively than the lower pressures. The fact also emerges that there is no sound statistical evidence that Visken is more effective for either of the sexes or that efficacy of therapy shows predeliction for a specific age group. Visken was well tolerated and showed no significant side-effects.Keywords
This publication has 5 references indexed in Scilit:
- THE USE OF PRINDOLOL (VISKEN) IN THE TREATMENT OF HYPERTENSIONThe Medical Journal of Australia, 1972
- A potent β-adrenoreceptor blocking drug: 4-(2-hydroxy-3-isopropylaminopropoxy)indoleJournal of Pharmacy and Pharmacology, 1970
- Studies with LB 46, a new β-receptor blocking drugEuropean Journal of Pharmacology, 1969
- ANTIHYPERTENSIVE THERAPY WITH ALPRENOLOL, Aβ‐ADRENERGIC RECEPTOR ANTAGONISTActa Medica Scandinavica, 1969
- Treatment of Hypertension with PropranololBMJ, 1969